Iradimed (NASDAQ:IRMD) Issues Q1 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.390-0.430 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $19.2 million-$19.4 million, compared to the consensus revenue estimate of $19.1 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Price Performance

IRMD opened at $55.23 on Friday. The stock has a 50-day moving average price of $57.20 and a 200-day moving average price of $52.10. The firm has a market cap of $699.76 million, a PE ratio of 37.83 and a beta of 0.82. Iradimed has a 1 year low of $40.18 and a 1 year high of $63.29.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.05). Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, sell-side analysts anticipate that Iradimed will post 1.52 EPS for the current year.

Iradimed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 5th. Investors of record on Monday, February 24th will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 1.23%. This is an increase from Iradimed’s previous quarterly dividend of $0.15. The ex-dividend date is Monday, February 24th. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IRMD shares. StockNews.com downgraded Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday. Roth Mkm reiterated a “buy” rating and issued a $72.00 price objective (up from $60.00) on shares of Iradimed in a report on Friday.

Insider Buying and Selling at Iradimed

In other news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.